NAMUR, Belgium, Dec. 2, 2013 /PRNewswire/ -- VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ® assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition's two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.
Earlier this month, VolitionRx presented preliminary data from a 90 patient independent trial, later confirmed in a further 113 patients, at University Hospital Bonn in Germany. This data demonstrated 75% detection rates at 70% specificity when using a single NuQ assay. The Belgian team confirmed these results using the same single assay, but when combining it with another nucleosome biomarker they achieved even better results. They have now analysed 39 patients' samples from the ongoing prospective trial which includes both healthy patients and patients with benign colon disorders.
"This increased detection rate confirms our original hypothesis that combining nucleosomes increases the accuracy of the test," comments Dr. Jake Micallef, Chief Scientific Officer of VolitionRx. "We hope to further increase the sensitivity and specificity by adding more biomarkers and developing a larger panel of nucleosome tests."
Current diagnostic screening practices for colorectal cancer vary globally, from inviting at-risk groups to submit faecal occult blood tests to offering regular investigative colonoscopies. Unfortunatel
|SOURCE VolitionRx Limited|
Copyright©2012 PR Newswire.
All rights reserved